Talk:Axicabtagene ciloleucel
Latest comment: 6 years ago by Quisqualis in topic What is the risk eg of CRS
| This is the talk page for discussing improvements to the Axicabtagene ciloleucel article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Axicabtagene ciloleucel.
|
Different co-stimulatory domain ?
edit[1] says "Both of the approved therapies target CD19, a protein expressed in the surface of lymphoma and leukemia cells. The primary difference between the two products is the co-stimulatory domain. Upon binding CD19, the drugs induce different co-stimulatory signals to activate an immune response." - Could explain with RS. - Rod57 (talk) 14:02, 21 October 2017 (UTC)
What is the risk eg of CRS
editTwice the article mentions risk of CRS etc - but what % is the risk, and is it theoretical (based on what) or measured in clinical trials (which) ? - Rod57 (talk) 16:40, 14 December 2017 (UTC)
- There appear to be only 2 other editors besides yourself on this article. You are free to contact them with your inquiry, but will likely be the one to add the % of risk figure to the article.--Quisqualis (talk) 05:49, 15 December 2017 (UTC)